Application of different nanoparticles in the diagnosis of colorectal cancer

Ghorbani, Fatemeh; Kokhaei, Parviz; Ghorbani, Majid; Eslami, Majid

doi:10.1016/j.genrep.2020.100896

Cited by 18 publications

(29 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the organic NPs are the micelles, which are spherical macromolecules formed by a hydrophilic outer layer and a hydrophobic interior in an aqueous solution [ 92 ]. This type of nanocarrier is thermodynamically stable as well as considered nontoxic and safe due to its composition of biocompatible material, being able to transport hydrophobic drugs, in vivo, inside or on the surface through a covalent connection with the carrier [ 92 ]. Its small diameter allows for the gradual administration of drugs and prevents their recognition by the immune system and their filtration by the spleen epithelial cells.…”

Section: Nanoparticles As Drug Delivery Systemsmentioning

confidence: 99%

Nanocarriers as a Tool for the Treatment of Colorectal Cancer

et al. 2021

View full text Add to dashboard Cite

Nanotechnology is a promising tool for the treatment of cancer. In the past decades, major steps have been made to bring nanotechnology into the clinic in the form of nanoparticle-based drug delivery systems. The great hope of drug delivery systems is to reduce the side effects of chemotherapeutics while simultaneously increasing the efficiency of the therapy. An increased treatment efficiency would greatly benefit the quality of life as well as the life expectancy of cancer patients. However, besides its many advantages, nanomedicines have to face several challenges and hurdles before they can be used for the effective treatment of tumors. Here, we give an overview of the hallmarks of cancer, especially colorectal cancer, and discuss biological barriers as well as how drug delivery systems can be utilized for the effective treatment of tumors and metastases.

show abstract

Section: Nanoparticles As Drug Delivery Systemsmentioning

confidence: 99%

Nanocarriers as a Tool for the Treatment of Colorectal Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The frequency of CRC is 22.8% per 100,000 people aged between 40 and 49 and 6.8% in 30 t 39 years [15]. The comparative risk of emerging CRC is lower in those people who have more physical activities as compared to that who are not involve in physical activities [16].…”

Section: Introductionmentioning

confidence: 99%

“…Many technologies have now been emerged to treat cancer and types of cancer e.g., [1] have used the ethanolic extract of Allacanthos crab against cancer cells and concluded that this extract might be potential source of curing cancer cells. Nanotechnology is one of the important and emerging field of science that act as drug delivery, medicine, and anti-cancer agent [15]. The nanoparticles are small nanosized materials 1-100 nm in size [19], that might act as potential source for cancer cells [20].…”

Section: Introductionmentioning

confidence: 99%

Mutation analysis of TP53 in colorectal cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer is a kind of solid tumor and third most common of cancer which leads to death. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. The present study was aimed to reveal the mutation at TP53 in Peshawar Pakistan.Material and methods: For this purpose, a total of 50 blood samples in EDTA tubes was collected from Peshawar with complete information of patients using questionnaire. The polymerase chain reaction was performed.Results: The results of the present study have revealed that the ratio of colorectal cancer in males is higher 62% than females (38%). Histopathological results have indicated that moderately differentiated adenocarcinoma is 25 (50%) followed by poorly differentiated adenocarcinoma 15 (30%), Well-differentiated adenocarcinoma 8 (16%), and Metastatic adenocarcinoma 2 (4%) in 50 colorectal cancer patients. The nucleotide sequence of the human TP53 gene of colorectal cancer patients was aligned with the human wild-type TP53 database sequence with NC_191170 (NCBI) using CLUSTALW. After BLASTING, the mutation was found in exon 5 and exon 7 of TP53, while no mutation was found in exon 8 of TP53. That patient in which point mutation was found in exon 5 and 7 respectively showed less survival as compared to that of colorectal cancer patients having no point mutation in the TP53 gene. Conclusion:The present study concluded that point mutations were found in exons 5&7 of the TP53 gene and patients having TP53 gene mutations shown less survival rate compared to colorectal cancer patients having no mutations.

show abstract

“…The frequency of CRC is 22.8% per 100,000 people aged between 40 and 49 and 6.8% in 30 t 39 years (Ghorbani et al, 2020). The comparative risk of emerging CRC is lower in those people who have more physical activities as compared to that who are not involve in physical activities (Zhang et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

“…Nanotechnology is one of the important and emerging eld of science that act as drug delivery, medicine, and anti-cancer agent (Ghorbani et al, 2020). The nanoparticles are small nano-sized materials 1-100 nm in size (Kakakhel et al, 2019), that might act as potential source for cancer cells (Brigger et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Mutation Analysis of TP53 in Colorectal Cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.

Ali

Fayyaz

Anwar

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Colorectal cancer is a kind of solid tumor and third most common of cancer which leads to death. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. For this purpose, a total of 50 blood samples in EDTA tubes was collected from Peshawar with complete information of patients using questionnaireResult The results of the present study indicate that the ratio of CRC in males is higher 62% than females (38%). Histopathological results indicate that moderately differentiated adenocarcinoma is 25 (50%) followed by poorly differentiated adenocarcinoma 15 (30%), Well-differentiated adenocarcinoma 8 (16%), and Metastatic adenocarcinoma 2 (4%) in 50 CRC patients. Grading distribution indicating 34% of patients were having a high grade of carcinoma while 66% had low-grade carcinoma. The nucleotide sequence of the human TP53 gene of CRC patients was aligned with the human wild-type TP53 database sequence with NC_191170 (NCBI) using CLUSTALW. After BLASTING, the mutation was found in exon 5 and exon 7 of TP53, while no mutation was found in exon 8 of TP53. That patient in which point mutation was found in exon 5 and 7 respectively showed less survival as compared to that of colorectal cancer patients having no point mutation in the TP53 gene.Conclusion The present study concluded that point mutations were found in exons 5 & 7 of the TP53 gene and patients having TP53 gene mutations shown less survival rate compared to CRC patients having no mutations.

show abstract

Application of different nanoparticles in the diagnosis of colorectal cancer

Cited by 18 publications

References 63 publications

Nanocarriers as a Tool for the Treatment of Colorectal Cancer

Nanocarriers as a Tool for the Treatment of Colorectal Cancer

Mutation analysis of TP53 in colorectal cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.

Mutation Analysis of TP53 in Colorectal Cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.

Contact Info

Product

Resources

About